发明名称 |
Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
摘要 |
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge. |
申请公布号 |
US8877708(B2) |
申请公布日期 |
2014.11.04 |
申请号 |
US201013375810 |
申请日期 |
2010.06.07 |
申请人 |
VeroScience, LLC |
发明人 |
Cincotta Anthony H. |
分类号 |
A61K38/00;A61P3/10;A61K31/4453;A61K38/28;A61K31/195;A61K38/22;A61K38/26;A61K31/00;A61K31/165;A61K45/06;A61K31/48;A61K31/4985 |
主分类号 |
A61K38/00 |
代理机构 |
Fish & Richardson P.C. |
代理人 |
Fish & Richardson P.C. |
主权项 |
1. A method of treating a metabolic disorder or key elements of a metabolic disorder, such method comprising the step of administering to a patient in need of such treatment daily (a) a dopamine receptor agonist; and (b) a first-phase insulin secretagouge selected from the group consisting of glucagon like peptide-1 (GLP-1) or an analog thereof, a dipeptidyl peptidase inhibitor, gastric inhibitory polypeptide (also known as glucose-dependent insulinotropic peptide), a meglitinide, repaglinide, nataglinide and short acting insulin, wherein the dosage of each of said dopamine receptor agonist and first-phase insulin secretagouge in combination, provides a therapeutic effect greater than the additive effect of administering the same dosage of each of said dopamine receptor agonist and first-phase insulin secretagouge alone. |
地址 |
Tiverton RI US |